A Follow up Study to Protocol 101/2 - Continued Treatment by IPL344 IV
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
This is a prospective, open-label, follow up study to protocol 101/2 - continued treatment by
IPL344 IV administered once a day in up to 15 participants with ALS.
The study is designed to determine the safety, tolerability and initial efficacy of IPL344,
administered once a day, by IV infusion for up to 36 months